Aug 27, 2013
Laureate Develops Dyax Candidate into Phase I Trials
Dyax says the entry of its human antibody drug candidate DX-2930 into clinical trials is thanks to successful development and up-scale manufacturing by Laureate Biopharma.
BioCryst offering price nigh
Durham drug developer BioCryst Pharmaceuticals hopes to rake in cash with a stock offering of $20 million to fund clinical and pre-commercialization for its newly buzzed-about compounds.
The Motley Fool
A Biotech's Swelling Valuation
Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today.
Santarus says FDA accepts Ruconest application Santarus Inc. and...
Santarus Inc. and Pharming Group said Tuesday that the Food and Drug Administration accepted their marketing application for the hereditary angioedema drug Ruconest, and will make a decision in 10 months.